Donor Liver Blood Tests and Liver Transplant Outcomes: UK Registry Cohort Study.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
28
11
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
Safely increasing organ utilization is a global priority. Donor serum transaminase levels are often used to decline livers, despite minimal evidence to support such decisions. This study aimed to investigate the impact of donor "liver blood tests" on transplant outcomes. This retrospective cohort study used the National Health Service registry on adult liver transplantation (2016-2019); adjusted regressions models were used to assess the effect of donor "liver blood tests" on outcomes. A total of 3299 adult liver transplant recipients were included (2530 following brain stem death, 769 following circulatory death). Peak alanine transaminase (ALT) ranged from 6 to 5927 U/L (median = 45). Donor cause of death significantly predicted donor ALT; 4.2-fold increase in peak ALT with hypoxic brain injury versus intracranial hemorrhage (adjusted P < 0.001). On multivariable analysis, adjusting for a wide range of factors, transaminase level (ALT or aspartate aminotransferase) failed to predict graft survival, primary nonfunction, 90-d graft loss, or mortality. This held true in all examined subgroups, that is, steatotic grafts, donation following circulatory death, hypoxic brain injury donors, and donors, in which ALT was still rising at the time of retrieval. Even grafts from donors with extremely deranged ALT (>1000 U/L) displayed excellent posttransplant outcomes. In contrast, donor peak alkaline phosphatase was a significant predictor of graft loss (adjusted hazard ratio = 1.808; 1.016-3.216; P = 0.044). Donor transaminases do not predict posttransplant outcomes. When other factors are favorable, livers from donors with raised transaminases can be accepted and transplanted with confidence. Such knowledge should improve organ utilization decision-making and prevent future unnecessary organ discard. This provides a safe, simple, and immediate option to expand the donor pool.
Sections du résumé
BACKGROUND
BACKGROUND
Safely increasing organ utilization is a global priority. Donor serum transaminase levels are often used to decline livers, despite minimal evidence to support such decisions. This study aimed to investigate the impact of donor "liver blood tests" on transplant outcomes.
METHODS
METHODS
This retrospective cohort study used the National Health Service registry on adult liver transplantation (2016-2019); adjusted regressions models were used to assess the effect of donor "liver blood tests" on outcomes.
RESULTS
RESULTS
A total of 3299 adult liver transplant recipients were included (2530 following brain stem death, 769 following circulatory death). Peak alanine transaminase (ALT) ranged from 6 to 5927 U/L (median = 45). Donor cause of death significantly predicted donor ALT; 4.2-fold increase in peak ALT with hypoxic brain injury versus intracranial hemorrhage (adjusted P < 0.001). On multivariable analysis, adjusting for a wide range of factors, transaminase level (ALT or aspartate aminotransferase) failed to predict graft survival, primary nonfunction, 90-d graft loss, or mortality. This held true in all examined subgroups, that is, steatotic grafts, donation following circulatory death, hypoxic brain injury donors, and donors, in which ALT was still rising at the time of retrieval. Even grafts from donors with extremely deranged ALT (>1000 U/L) displayed excellent posttransplant outcomes. In contrast, donor peak alkaline phosphatase was a significant predictor of graft loss (adjusted hazard ratio = 1.808; 1.016-3.216; P = 0.044).
CONCLUSIONS
CONCLUSIONS
Donor transaminases do not predict posttransplant outcomes. When other factors are favorable, livers from donors with raised transaminases can be accepted and transplanted with confidence. Such knowledge should improve organ utilization decision-making and prevent future unnecessary organ discard. This provides a safe, simple, and immediate option to expand the donor pool.
Identifiants
pubmed: 37069657
doi: 10.1097/TP.0000000000004610
pii: 00007890-990000000-00389
doi:
Substances chimiques
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2533-2544Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.This research was supported by the National Institute for Health Research Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge in collaboration with Newcastle University and in partnership with National Health Service Blood and Transplant.
Références
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
Julien J, Ayer T, Tapper EB, et al. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study. Hepatology. 2022;75:1480–1490.
Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75:1476–1484.
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250–261.
NHS Blood and Transplant. Annual report on liver transplantation (2019/2020). Available at www.odt.nhs.uk/statistics-and-reports/organ-specific-reports . Accessed January 28, 2023.
Neuberger J, Callaghan C. Organ utilization—the next hurdle in transplantation? Transpl Int. 2020;33:1597–1609.
Kaltenbach MG, Harhay MO, Abt PL, et al. Trends in deceased donor liver enzymes prior to transplant: the impact on graft selection and outcomes. Am J Transplant. 2020;20:213–219.
Eurotransplant. Eurotransplant organ match characteristics. Available at https://www.eurotransplant.org/organ-match-characteristics/ . Accessed July 20, 2022.
Hann A, Nutu A, Clarke G, et al. Normothermic machine perfusion—improving the supply of transplantable livers for high-risk recipients. Transpl Int. 2022;35:10460.
European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–485.
Vodkin I, Kuo A. Extended criteria donors in liver transplantation. Clin Liver Dis. 2017;21:289–301.
NHS Blood and Transplant. Slides and presentations. Available at https://www.odt.nhs.uk/statistics-and-reports/slides-and-presentations . Accessed January 28, 2023.
Rampes S, Ma D. Hepatic ischemia-reperfusion injury in liver transplant setting: mechanisms and protective strategies. J Biomed Res. 2019;33:221–234.
Taylor R, Allen E, Richards JA, et al.; Liver Advisory Group to NHS Blood and Transplant. Survival advantage for patients accepting the offer of a circulatory death liver transplant. J Hepatol. 2019;70:855–865.
von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
Tingle SJ, Thompson ER, Ali SS, et al. Risk factors and impact of early anastomotic biliary complications after liver transplantation: UK registry analysis. BJS Open. 2021;5:zrab019.
Bennette C, Vickers A. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol. 2012;12:21.
Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127–141.
Collins GS, Ogundimu EO, Cook JA, et al. Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model. Stat Med. 2016;35:4124–4135.
Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. 2nd ed. New York, NY: Springer; 2015.
Mangus RS, Fridell JA, Kubal CA, et al. Elevated alanine aminotransferase (ALT) in the deceased donor: impact on early post-transplant liver allograft function. Liver Int. 2015;35:524–531.
Chen Z, Wang T, Chen C, et al. Transplantation of extended criteria donor livers following continuous normothermic machine perfusion without recooling. Transplantation. 2022;106:1193–1200.
Czigany Z, Pratschke J, Froněk J, et al. Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death: results from a multicenter randomized controlled trial (HOPE ECD-DBD). Ann Surg. 2021;274:705–712.
Braat AE, Blok JJ, Putter H, et al.; European Liver and Intestine Transplant Association (ELITA) and Eurotransplant Liver Intestine Advisory Committee (ELIAC). The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant. 2012;12:2789–2796.
Collett D, Friend PJ, Watson CJ. Factors associated with short- and long-term liver graft survival in the United Kingdom: development of a UK donor liver index. Transplantation. 2017;101:786–792.
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index [published correction appears in Am J Transplant. 2018;18(12):3085]. Am J Transplant. 2006;6:783–790.
Winter A, Féray C, Audureau E, et al. A donor quality index for liver transplantation: development, internal and external validation [published correction appears in Sci Rep. 2018;8(1):15109]. Sci Rep. 2018;8:9871.
Cuende N, Miranda B, Cañón JF, et al. Donor characteristics associated with liver graft survival. Transplantation. 2005;79:1445–1452.
Fakhar N, Nikeghbalian S, Kazemi K, et al. Transplantation of deceased donor livers with elevated levels of serum transaminases at Shiraz transplant center. Hepat Mon. 2016;16:e40140.
Radunz S, Paul A, Nowak K, et al. Liver transplantation using donor organs with markedly elevated liver enzymes: how far can we go? Liver Int. 2011;31:1021–1027.
Capelli R, Kitano Y, Linhares M, et al. The prognostic significance of serum aspartate transaminase and gamma-glutamyl transferase in liver deceased donors. Transpl Int. 2021;34:2247–2256.
Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J. 2016;92:223–234.
Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci. 1993;38:2145–2150.
Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050–2068.
Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65:253–259.
Martins PN, Rizzari MD, Ghinolfi D, et al.; ILTS Special Interest Group “DCD, Preservation and Machine Perfusion.Design, analysis, and pitfalls of clinical trials using ex situ liver machine perfusion: the international liver transplantation society consensus guidelines. Transplantation. 2021;105:796–815.
Gilgenkrantz H, Collin de l’Hortet A. Understanding liver regeneration: from mechanisms to regenerative medicine. Am J Pathol. 2018;188:1316–1327.
Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286–300.
Neil DAH, Mergental H, Hann A, et al. Is hepatocyte necrosis a good marker of donor liver viability during machine perfusion? Hepatol Commun. 2022;6:435–436.
Hann A, Lembach H, Alzoubi M, et al. Hepatocyte necrosis on liver allograft biopsy: normothermic machine perfusion is the ideal platform for using these grafts in high-risk recipients. Clin Transplant. 2021;35:e14380.
Younes R, Burgoyne R, Tiniakos D, et al. Clinical implications of hepatic progenitor cell activation in non-alcoholic fatty liver disease. Hepatoma Res. 2021;7:15.
Raven A, Forbes SJ. Hepatic progenitors in liver regeneration. J Hepatol. 2018;69:1394–1395.
Raven A, Lu WY, Man TY, et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration [published correction appears in Nature . 2018;555(7696):402]. Nature. 2017;547:350–354.
Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006;40:633–635.
Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.